This sponsored supplement was produced by Focus Reports.
Project Coordinator: Alina Manac, Aleksandra Klassen
Editorial Coordinator: Herbert Mosmuller
Project Publisher: Julie Avena
Contribution: Mary Carmen Luna Matuk
For exclusive interviews and more info, please log onto
http://www.pharmaboardroom.com/ or write to email@example.com
Öresund bridge HDR, Håkan Dahlström
On the Northern fringes of Europe, those who want to believe that there is a sustainable future for the old continent's generous
healthcare systems find a beacon of hope.
At a time when the healthcare systems of most of the European Union's member states are going through their biggest existential
crisis in post-war history, the Nordics (Denmark, Finland, Iceland, Norway, and Sweden) maintain sustainable yet technologically
advanced healthcare systems.
Furthermore, the region's most populous nations (and the focus of this report), Sweden and Denmark, have made impressive contributions
to the world's life sciences industry.
Denmark, a country of 5.6 million, brought the world such pharmaceutical champions as Novo Nordisk, Lundbeck, Leo Pharma,
and ALK. Sweden, population of 9.5 million, grooms a thriving life sciences industry while its pharmaceutical market, the
largest in the region, is often considered the barometer of Europe due to its progressive nature.
Denmark and Sweden coming out on top amid fierce competition, despite their modest populations, is often ascribed to the 'Nordic
model.' This slightly undefined concept refers to a consensus-based model with a focus on sustainability and high levels of
trust and cooperation between government and industry. Is the 'Nordic model' really the key explanation behind the remarkable
success of the Danish and Swedish life sciences industry?
MAKING A VIRTUE OF NECESSITY?
"The Nordic region—the 'quiet North' as it could have been called—counterbalances the turbulence in Southern Europe," said
Zinta Krumins, managing director Nordics, Boehringer Ingelheim, when asked about the relevance of the Nordics to the company.
"The Nordics are a very stable region, with small but reasonable growth prospects, very good government structures and frameworks,
social infrastructure and a solid economy."
Zinta Krumins, Managing Director Nordics, Boehringer Ingelheim
Although attractive for their stable economies and governments, the Nordics do not have numbers on their side. "We cannot
compete in terms of volume and economy of scale," said Stig Jørgensen, CEO of Medicon Valley Alliance, a network organization
representing human life sciences in Medicon Valley, a region spanning eastern Denmark and south-western Sweden.
Stig Jørgensen, CEO, Medicon Valley Alliance
Thus, the countries need to work together in order to increase their leverage. "Other countries often have an individualistic
mindset and their culture revolves around competing with each other," Jørgensen continued. "Our collective culture enables
us to unite doctors, engineers, and business people to work together. All these disciplines collaborating and working in
the same domain is where innovation will flourish."
Dorthe Mikkelsen, Senior Vice-President Mid-Europe 2, MSD
With Sweden and Denmark taking spot one and three respectively on the European Commission's Innovation Union Scoreboard 2013,
it is hard to argue against the effectiveness of the model.
Mary Di Marzio, General Manager Nordics, Shire Plc
For instance, both Sweden and Denmark are overrepresented in clinical trials. MSD conducts about 10 percent of all its clinical
trials in the Nordic region. "The attractiveness of the Nordics is a health care system that is state of the art, with strong
medical professionals, a high level of scientific leaders both at the universities and at the clinics, and an overall strong
infrastructure for clinical research," said Dorthe Mikkelsen, Senior Vice-President Mid-Europe 2, MSD. Furthermore, the Nordics
offer a good data foundation. "Their registries are a goldmine for doing research and developing new products," Mikkelsen
Biotech as Business—the Bavarian Nordic story
Clinical trials are also seen as another avenue for innovation, with many companies breaking out of the traditional sales
model. "We see clinical trials as a positive way to collaborate with health care professionals," Tommy Söderman, general manager
Nordics, IPSEN, said. "In the Nordics we have many of our own initiatives; for example, we are running clinical trials on
rehab patients recovering from strokes at 30 sites in the Nordic region."
Pia Olsen Dyhr, Minister of Trade & Investment, Denmark
The two countries are also a goldmine for acquisitions. Shire Plc recently acquired Swedish biotech Premacure, a biotech developing
a therapy for the prevention of retinopathy of prematurity, currently in Phase II.
Christian Dyvig, CEO, Lundbeck Foundation
"Before Premacure became part of Shire, the company was already surrounded by an environment that allowed them to invest,
explore and discover, which we then found was a good fit for us. Sweden provides an environment in which government incentivizes
companies to be innovative and rewards innovation with favorable taxation," said Mary Di Marzio, General Manager Nordics with
Shire Plc. "That is at the core of what the Nordic nations are encouraged to do and are rewarded for doing."
Anders Hedegaard, CEO of Bavarian Nordic